A phase 3 trial of magrolimab + AZA vs. standard of care in TP53 mutated AML is ongoing (ENHANCE2, NCT04778397), and a phase 3 randomized trial of AZA + magrolimab or placebo in MDS is recruiting (ENHANCE trial—NCT04313881). The gene discussed is TP53; the disease is acute myeloid leukemia.